 Neurocrine once again posted disappointing Ingrezza sales, and while the post-pandemic reopening should help, it likely wont be an immediate recovery. Management is advancing a broad pipeline of high-riskhigh-reward candidates into Phase II studies for a range of movement and psychiatric disorders. 